Showing 2861-2870 of 3415 results for "".
- FDA Issues Warning to Matte Beauty Over Unapproved Chemical Peelshttps://practicaldermatology.com/news/fda-issues-warning-matte-beauty-over-unapproved-chemical-peels/2467661/The U.S. Food and Drug Administration (FDA) recently sent a warning letter to Matte Beauty, addressing what the agency described as significant regulatory violations regarding their chemical peel products. According to the July 25 letter, the products in question include “TCA 100% Skin Pe
- FDA Approves Deuruxolitinib for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-deuruxolitinib-alopecia-areata/2467563/The U.S. Food and Drug Administration (FDA) has approved deuruxolitinib 8-mg tablets for the treatment of adults with severe alopecia areata, Sun Pharmaceuticals Industries Limited announced in a press release. Deuroxolitinib is available from Sun Pharma under the name LEQSELVI. "
- Commentary: Beware Impact of TikTok's Algorithm on Dermatological Information Disseminationhttps://practicaldermatology.com/news/commentary-beware-impact-tiktoks-algorithm-dermatological-information-dissemination/2467491/A recent commentary in The Journal of Drugs in Dermatology exploring concerns about the dissemination of dermatological information on T
- sNDA Submitted for Roflumilast Foam 0.3% for Scalp and Body Psoriasishttps://practicaldermatology.com/news/snda-submitted-roflumilast-foam-03-scalp-and-body-psoriasis/2467457/A supplemental New Drug Application (sNDA) has been submitted for ZORYVE (roflumilast) foam 0.3%, a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis, Arcutis Biotherapeutics, Inc., announce
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Biofrontera Unveils New Red-Light-Emitting Lamp for PDT on Actinic Keratoseshttps://practicaldermatology.com/news/biofronters-unveils-new-red-light-emitting-lamp-pdt-actinic-keratoses/2467140/Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate sever
- FDA Approves Gel for Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-gel-axillary-hyperhidrosis/2467109/The US Food and Drug Administration (FDA) has approved a new prescription gel used to treat axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 and older, manufacturer Botanix Pharmaceuticals announced. Sofdra (sofpironium) is the first chemical entity approved b
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J
- Analysis: Few Dermatologists Share Sun Protection Advice on TikTokhttps://practicaldermatology.com/news/analysis-few-dermatologists-share-sun-protection-advice-tiktok/2467072/A new analysis in the Journal of Drugs in Dermatology shows a significant gap in the presence of board-certified dermatologists (BCDs) on TikTok, particularly concerning sun protection content. "Limited studies have analyzed sources of TikTok videos associated with sun safety and